Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux
Launched by MUHAMMAD AAMIR LATIF · Mar 22, 2025
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Since the FDA issued a warning against domperidone as a potential proarrhythmic drug in children, its use has been widely discouraged and no longer recommended in safe practices. This warning at one end persuaded the pediatricians to search for the new options; on the other end, the use of metoclopramide, H2 receptor antagonists, and alginate-based medications became superfluous, opening a wide area of research in search of the next potential best option. The findings of this study would add to the existing statistics and help clinicians to have better outcomes among infants with gastroesop...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants of any gender
- • Aged 1-12 months
- • Presenting with symptoms of gastroesophageal reflux disease not responding to dietary modifications and positioning
- • Afebrile at the time of presentation
- • Vitally stable
- Exclusion Criteria:
- • No evidence of hypertrophic pyloric stenosis on ultrasonography
- • Children with congenital heart disease
- • Any history of prior illness associated with symptoms
- • With abdominal distension
- • Neurological impairment, like developmentally delayed, grossly microcephalic
About Muhammad Aamir Latif
Muhammad Aamir Latif is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical research and a focus on innovative therapeutic solutions, he collaborates with healthcare professionals and institutions to design, implement, and oversee clinical trials. His expertise encompasses various therapeutic areas, ensuring adherence to regulatory standards and ethical guidelines. Through strategic partnerships and a patient-centered approach, Muhammad Aamir Latif aims to contribute significantly to the development of safe and effective treatments, fostering advancements in healthcare and enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dera Ghazi Khan, Punjab, Pakistan
Patients applied
Trial Officials
Irum Jabeen, FCPS
Principal Investigator
Allama Iqbal Teaching Hospital, Dera Ghazi Khan, Pakistan
Asma Akbar, FCPS
Principal Investigator
Allama Iqbal Teaching Hospital, Dera Ghazi Khan, Pakistan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported